Active Mental Health Psychology & Behaviour

How does the SSRI fluoxetine work in adolescent depression?

In plain English

AI plain-English summary

Fluoxetine, the antidepressant sold as Prozac, is known to work in depressed teenagers, but no one understands exactly how it changes their brain function to lift their mood. Depression in adolescents differs from adult depression in symptoms, diagnosis, and treatment response. Anger and irritability, for example, are core features of youth depression but are less prominent in adults. Despite fluoxetine being the only SSRI approved for adolescents, researchers lack a clear experimental model of how the drug acts on the developing brain. This project fills that gap by taking a developmental approach, combining human studies with adolescent rodent models to isolate the neurocognitive markers of fluoxetine treatment. If successful, this work will produce a mechanistic model of SSRI action specific to young people. That model could then be used to design better treatments—drugs or therapies that target the right brain circuits for adolescent depression, reduce side effects, and manage withdrawal more safely. The research is fundamental science: it aims to understand a biological mechanism, not to test a new drug. But similar foundational work on adult depression has already reshaped how psychiatrists think about treatment response. A clearer picture of what fluoxetine actually does in the teenage brain could eventually lead to more precise, age-appropriate care.

View original technical description
The efficacy of the selective serotonin reuptake inhibitor (SSRI) fluoxetine has been well characterized in young people with depression. However, our understanding of how SSRIs work in this age group is still in its infancy. Developmental differences affect symptoms, diagnosis, and treatment response in depression, highlighting the need for age-specific development of experimental medicine models to understand treatment action. The current proposal will therefore take a developmental and interdisciplinary approach to analyse how fluoxetine affects neurocognitive function relevant to adolescents with depression. WP1 defines the measures used in this work together with our young advisors with lived experience and utilizing pilot data from our lab focused on anger/irritability, a core debilitating presentation of youth depression. We will perform detailed mechanistic studies in healthy volunteers to isolate markers of fluoxetine treatment (WP2) and apply these to adolescent depression to characterise mechanisms of clinical response (WP4) as well as withdrawal from treatment (WP5). We will also use complementary affective models in adolescent rodent models to refine our mechanistic model development (WP3). A better understanding of the mechanisms underpinning the effects of SSRIs in young people with depression will help formulate human experimental medicine models to optimize treatments of the future.

View the original record at the funder ↗

Researchers

Argyris Stringaris (EPMC Awardee)Catherine Harmer (EPMC Awardee)Emma Robinson (EPMC Awardee)Liliana Capitao (EPMC Awardee)Marieke Martens (EPMC Awardee)Susannah Murphy (EPMC Awardee)

Related Research

Grants with similar aims, by meaning.

Impact of early life SSRI exposure on neural circuit formation and function
The effects of fluoxetine on anger processing in male healthy volunteers
Better targetting of antidepressants in older people: the influence of age and genetic background on serotonin signalling.
FenDep: Using fenfluramine to test the serotonin deficiency theory of depression
Neurocognitive predictors of adolescent depression: a high risk longitudinal study

Original classification

Directed Call - full

Plain English summaries and category classifications on this site are generated by AI and may not perfectly reflect the original research.